Cure is an early-stage startup founded in 2019 with the vision to offer access to healthcare services in patients' homes. The platform connects patients with local pharmacies providing a catalog of more than 2500 products that can be ordered through their app. Cure will provide access to healthcare professionals, such as doctors and nurses, who can provide medical care and advice remotely.
Cure is a one-stop shop for on-demand healthcare services provided through a mobile app. One of Cure's most significant features is its product availability; given the network of pharmacies they have built, users can find almost any needed product and deliver it on the same day.
Cure's platform is integrated with the pharmacy's inventory systems, and they have a fleet of riders to deliver the products on time. Users can also talk to a pharmacist when ordering their medicines, offering the same level of support patients would get in a physical store.
Cure is getting ready to launch new services where users will be able to connect with healthcare professionals such as doctors and physiotherapists. They will also offer access to mental health counseling with therapists and health coaches. Patients will be able to book virtual appointments with these professionals through Cures app. Additionally, they will launch e-prescriptions so patients can store and share their data with pharmacies.
On their B2B side, they offer local pharmacies the chance to scale their businesses digitally to expand their client reach. Cure can increase local pharmacies' revenues and growth by quickly digitizing and promoting their store and delivering their products to patients.
The demand for on-demand healthcare services is on the rise, particularly since the COVID-19 pandemic, this has accelerated the adoption of telemedicine, and patients are increasingly seeking remote healthcare services. According to a report by Grand View Research, the telemedicine market is expected to grow at a compound annual growth rate (CAGR) of 25.1% from 2020 to 2027, which turns it into a highly attractive sector for angel investors and venture capitalists.
Cure also has significant opportunities to expand its services into emerging markets; they have announced plans to expand to over six countries in the European Union. By increasing their scope of services from telehealth services to delivery and electronic patient records, they will be able to integrate multiple service providers and offer a one-stop shop healthcare solution.
While Cure has significant opportunities for growth, there are also risks associated with operating in the healthcare industry that startup investors should be aware of. One of the most significant risks faced by startup companies in this sector is regulatory compliance. Healthcare regulations are complex and vary from country to country; this can be a difficult barrier to entry to surpass when looking to expand in and outside of the UE. Cure must ensure that it complies with all the relevant regulations and obtains the necessary licenses to operate in each market.
Another risk is cybersecurity. Cure will handle sensitive patient information since they plan to store electronic patient data and records. It must ensure its platform is secure and protected against cyber threats. Any patient data breach could damage Cure's reputation and result in legal action.
The healthcare industry is rapidly evolving. With the rise of digital technology, Cure can leverage its innovative platform and offer a comprehensive suite of healthcare services through a digital platform. The telehealth market is growing fast, and the solutions that can integrate various services into one platform will be the ones that can get ahead of the competition.
At aVenture, we are developing a user-friendly investment platform that will allow non-accredited and accredited investors to kick off their startup investing journey. Join aVenture to get access to our venture investing platform and start researching early-stage startups like Cure.
If you want to follow Cure's success story and start your investment journey, glimpse their startup profile on aVenture's platform.
Mar 30, 2023
Share:
Discover the next great startup opportunity with aVenture research updates.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.